ICON Plc ICLR 深 沪
等待开盘 04-03 09:30:00 美东时间
114.19
+2.770
+2.49%
华盛通- 最 高115.625
- 今 开110.06
- 成交量 66.09万股
- 最 低 108.58
- 昨 收 111.42
- 总市值 87.20亿
- 52周最高 210.9999
- 市盈率 静 11.98
- 换手率 0.87%
- 52周最低 66.57
- 委 比 18.69%
- 总股本 7635.99万
- 历史最高 347.7225
- 量 比 0.66
- 振 幅 6.32%
- 历史最低 15.03
- 每 手 1
- 风险率 27.91%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
Arm Holdings To Rally Over 27%? Here Are 10 Top Analyst Forecasts For Thursday
Wall Street analysts change ratings on top stocks: BNP Paribas cuts Chewy Inc, Bernstein cuts Qualcomm, Wells Fargo raises United Natural Foods.
03-26 21:08
BMO Capital Upgrades Icon to Outperform, Raises Price Target to $130
BMO Capital analyst Sean Dodge upgrades Icon (NASDAQ:ICLR) from Market Perform to Outperform and raises the price target from $100 to $130.
03-26 20:03
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
Barclays Maintains Equal-Weight on Icon, Lowers Price Target to $120
Barclays analyst Luke Sergott maintains Icon (NASDAQ:ICLR) with a Equal-Weight and lowers the price target from $200 to $120.
03-09 22:13
Here's How Much You Would Have Made Owning Icon Stock In The Last 20 Years
Icon (NASDAQ:ICLR) has outperformed the market over the past 20 years by 2.63% ...
02-26 04:47
美股大行评级 | 大摩将康宁目标价从103美元升至127美元；潜在涨幅1779.7%！IGC Pharma获Ascendiant Capital升目标价至5美元
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从4.75美元升至5美元；Brookline Capital：维持C4 Therapeutics"买入"评级，目标价从20美元升至30美元
02-24 10:27
Where Icon Stands With Analysts
In the last three months, 5 analysts have published ratings on Icon (NASDAQ:ICL...
02-24 03:01
美股大行评级 | 潜在涨幅216.49%！杰富瑞上调BioAge Labs目标价至62美元，评级升至"买入"
今日重点评级关注：杰富瑞：上调BioAge Labs评级至"买入"，目标价从9美元升至62美元；RBC Capital：维持COMPASS Pathways Plc Sponsored ADR"跑赢大市"评级，目标价从21美元升至22美元
02-19 16:21
